FY2025 · ended Dec 31, 2025 · Revenue $88.04M, +376.6% YoY · Filed Feb 26, 2026
Cytokinetics, Incorporated (CYTK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $88.0 million and a net loss of $785.0 million. Free cash flow was -$534.8 million. As of Sep 30, 2026 it held $1.6 billion in cash and investments and $539.8 million in total debt.
Revenue (TTM)
$113.29M
+29.9% vs year-ago TTM
Net income (TTM)
$-777.89M
-3.5% vs year-ago TTM
Operating cash flow (TTM)
$-571.97M
-32.1% vs year-ago TTM
Free cash flow (TTM)
$-588.58M
-29.8% vs year-ago TTM
EPS (TTM)
$-6,019.62
+4.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
123.16M
+4.0% vs prior year
Net cash
$1.04B
as of Sep 30, 2026
Operating margin
-625.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYTK (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1061983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M | -$186.3M |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M | -$215.3M |
| Diluted EPS | -$6.54 | -$5.26 | -$5.45 | -$4.33 | — |
| Operating cash flow | -$510.0M | -$395.9M | -$414.3M | -$299.5M | -$142.5M |
| Free cash flow | -$534.8M | -$399.8M | -$415.7M | -$310.9M | -$191.4M |
| Total assets | $1.4B | $1.4B | $824.3M | $1.0B | $841.3M |
| Total liabilities | $2.1B | $1.5B | $1.2B | $1.1B | $597.5M |
| Stockholders' equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M | $243.9M |
| Cash and investments | $1.2B | $1.2B | $655.4M | $829.3M | $623.7M |
| Total debt | $414.6M | $751.3M | $778.7M | $791.3M | $175.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Other events
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 1001 Cytokinetics, Incorporated SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.